The Problem

In 2020, it is believed that 1,7 million women in LMICs will develop breast cancer.

Early detection greatly increases the chances for successful treatment and recovery. The overall biggest prognostic factor to indicate the survival rate is the clinical stage when being diagnosed.

The earlier the stage – the higher the survival rate. The best preventative measure to elevate the survival rate is therefore to focus resources on early detection. Unfortunately, access to breast cancer screening and treatment varies greatly between countries.

The screening tools used today is not accessible for all women in LMICs, leaving many women without adequate screening. ThermaiScans solution is a cost effective portable risk assessment tool that can be used by health care professionals globally. It is an innovation with the potential to impact women’s health drastically thanks to its accessibility.

But – we can’t do it alone. If you are interested in joining in on our quest, please leave your e-mail below.

Be part of our journey

Leave your email to receive updates